| Document |
Document Title |
|
WO/1994/027439A1 |
This invention relates to pteridine and 8-deazapteridine compounds and compositions containing the same which are useful for controlling insects in agricultural crops. These pteridines may be represented by structure (I) wherein R and R1...
|
|
WO/1994/021636A1 |
Pterin derivatives having general formula (I) wherein R1 represents a group -(CHOH)2-CH3 or -(CHOH)2-CH2OH, R2 and R3 are not the same and represent either hydrogen or the group -(CH2)3CONH(CH2)4-NH-R4, wherein R4 represents hydrogen or ...
|
|
WO/1994/021613A1 |
The invention concerns compounds of formula (I) in which two of the symbols A, B, D and E stand each for CR1 and each of the other two symbols stands for CH or nitrogen, or one of the other two symbols stands for CH while the other stand...
|
|
WO/1994/017076A1 |
Novel compounds of formula (I) are found to inhibit the enzyme glycinamide ribonucleotide formyl transferase (GARFT). A novel method of preparing such compounds is also disclosed, as well as methods and compositions for employing the com...
|
|
WO/1994/014810A1 |
A compound represented by general formula (A), a salt thereof, and an antirheumatic containing at least one of them as the active ingredient, wherein R1 and R2 may be the same or different from each other and each represents hydrogen or ...
|
|
WO/1994/014780A1 |
The use of a compound which binds at the tetrahydrobiopterin site of NO synthase for the treatment of conditions where there is an advantage in inhibiting neuronal NO synthase with little or no inhibition of endothelial NO synthase is di...
|
|
WO/1994/011001A1 |
Disclosed are therapeutic compounds having the formula: (R)j - (core moiety), including resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is either non...
|
|
WO/1994/006431A1 |
Compounds comprise epoxide-substituted alkyl side chain (R) bonded to a core moiety, comprising Core moiety (I), wherein n is an integer from about 4 to about 16 and j is an integer from about 0 to about 12, including resolved enantiomer...
|
|
WO/1994/002148A1 |
The invention relates to a pharmaceutical composition for treating and alleviating the symptoms of vulvitis and vulvovaginitis. The compositions according to the invention comprises 0.05-0.5 % by weight of folic acid, 0.25-2.5 % by weigh...
|
|
WO/1993/022315A1 |
The invention relates to certain heteroaroyl-10-deazaaminopterin compounds, as well as a method and composition employing certain heteroaroyl-10-deazaaminopterin compounds for the treatment of inflammatory disease, such as rheumatoid art...
|
|
WO/1993/022316A1 |
A process is provided for the preparation of 10-deazaaminopterins and 5,10- and 8,10-dideazaaminopterins starting from the corresponding homoterephthalic acid diester, by coupling the corresponding dicarboxylic acid diester having formul...
|
|
WO1993020054A1 |
Fluorogenic chelators for Eu?3+ and Tb?3+ are provided, they form highly fluorescent complexes with Eu?3+ and Tb?3+. In all cases, the fluorescence observed was lanthanide-specific, long-lived and it was monitored by microsecond time-res...
|
|
WO/1993/019069A1 |
Intermediates and a process for the synthesis of 6-monosubstituted tetrahydropteridine C6-stereoisomers, including (6S)-tetrahydrofolic acid. The intermediates are shown in their two enantiomeric forms as above, wherein R1 and R2 are the...
|
|
WO/1993/017682A1 |
Compounds are disclosed having formula (I). The compounds of the invention are angiotensin II receptor antagonists.
|
|
WO/1993/017022A1 |
The (6S_) stereoisomer of folinic acid is obtained in high optical purity by salification of (R, S) folinic acid with di- or polyamines and subsequent selective crystallization of the desired diastereomeric salt.
|
|
WO/1993/015076A1 |
The treatment of racemic calcium folinate with a sodium salt of ethylendiaminotetraacetic acid and, preferably, calcium chloride determines the separation of a precipitate, whose mother liquors result enriched in a calcium salt of the le...
|
|
WO/1993/015077A1 |
A compound represented by general formula (II) and an antirheumatic containing the same as the active ingredient, wherein W represents a group represented by any of the general formulae (III), (IV), (V), (VI).
|
|
WO/1993/013102A1 |
5,10-Diakyl substituted 5,10-dideazaaminopterin and a cyclized derivative thereof are disclosed as potent antineoplastic agents. Also disclosed in an improved process for preparation of 10-ethyl-10-deazaaminopterin using the intermediate...
|
|
WO/1993/010118A1 |
Described is a method of preparing (6S)-5-methyl-tetrahydrofolic acid by separation of the racemic mixture, (6R,S)-5-methyl-tetrahydrofolic acid, using a base, characterized in that N-ethyl-2-aminomethylpyrrolidine or one of its optical ...
|
|
WO/1993/005784A1 |
An immunopotentiating and infection protective agent comprising riboflavin and/or a derivative thereof, which is safe for man, animal and so forth; an immunopotentiating and infection protective agent comprising riboflavin and/or a deriv...
|
|
WO/1993/004043A1 |
Compounds of formula (I) wherein Ar, W, Z, Q, R1, U, and T are as set forth herein, are described. These compounds are active as agents against retroviruses and in particular against HIV.
|
|
WO/1992/020687A1 |
Novel substituted fused pyrimidinones of formula (I) are useful as angiotensin II antagonists.
|
|
WO/1992/017173A2 |
The use of riboflavin or vitamin B2 for treating HIV-related diseases, herpes, retinitis pigmentosa and malaria is described. This molecule may be combined with vitamin PP or with AZT for treating HIV-related diseases. Clinical trials ha...
|
|
WO/1992/003436A1 |
A compound represented by general formula (A), which is useful as a medicine because it has potent antirheumatic, psoriasis curing and anticancer actions and a reduced toxicity, wherein R?1¿ represents CH¿2?, CH¿2?CH¿2?, CH¿2?O, CHÂ...
|
|
WO/1992/002241A1 |
The invention is a method of synthesizing tetrahydropteroylpoly-L-glutamic acid derivatives starting from the mono-L-glutamic acid derivative. The method has the advantage of not requiring any enzymes.
|
|
WO/1991/016330A1 |
The synthesis of gem-diphosphonic amethopterin(methotrexate) analogues, and their use as pharmaceutical compositions for various therapeutical applications, are described. In particular, an association of the pro-drug concept with the ph...
|
|
WO/1991/014433A1 |
A double blind clinical trial of 10-deazaaminopterin versus the antirheumatoid drug methotrexate (MTX) established that 10-deazaaminopterin, in addition to being at least equally effective as methotrexate in all respects in ameliorating ...
|
|
WO/1991/013890A2 |
The present invention concerns a new process for preparing diastereoisomers derived from tetrahydrofolic acid. By the reaction of (i) (6RS)-folinic acid or one of its salts or (ii) 5,10-methenyl-5,6,7,8-tetrahydrofolic acid with HCOOH at...
|
|
WO/1991/010677A1 |
In a process for enriching or cleaning biomolecules, the biomolecule is introduced into an aqueous-organic solvent system and salts are added to separate the phases. The pH at which the enrichment is carried out, suitable solvents for th...
|
|
WO/1991/010666A1 |
Three new non-polyglutamatable glutamic acid derivatives in the antifolate series are provided as well as procedures for their preparation. These compounds are: 4-amino-acid-4-deoxy-10-deazapteroyl-gamma-methyleneglutamic
acid, (1); 4-a...
|
|
WO/1991/001320A1 |
A method for the revovery of riboflavin from a fermentation broth or other feed stock is disclosed. The method comprises a process for the production of large, pure riboflavin crystals from an alkaline, aqueous solution containing solubi...
|
|
WO/1990/009382A1 |
Magnesium folates, process for their preparation, pharmaceutical compositions containing such folates and therapeutical applications where their supply can advantageously correct disorders and various conditions caused by deficiencies an...
|
|
WO/1990/004593A1 |
A compound having structure (I), in which R1 is hydrogen or a lower alkyl group and R2 is hydrogen or methyl.
|
|
WO/1989/011280A1 |
The invention relates to a new therapeutical utilization of a folinic substance or similar to the folinic acid, said utilization being characterized in that a substance selected amongst a group comprising the 5, 6, 7, 8-tetrahydrofolic a...
|
|
WO/1989/004312A1 |
Compounds having structure (I), in which R is -CO-Ar-COOR1 where R1 is hydrogen or lower alkyl, and pharmaceutical compositions containing the same exhibiting high growth inhibitory activity against methotrexate resistant cells.
|
|
WO/1988/008844A1 |
A process makes possible the production of (6S) folinic acids and their salts by recrystallization of alkaline earth salts of (6R, S) folinic acids, possibly by release of these acids contained in alkaline earth folinates and/or possibly...
|
|
WO/1988/004658A1 |
Compounds of general Formula (I), wherein Y is selected from alkyl, alkenyl, alkynyl, phenylalkyl or substituted or unsubstituted phenyl; n is an integer from 1 to 5; R1, R2, R3, R4 and X, which may be the same or different, are selected...
|
|
WO/1988/003025A1 |
Compounds and pharmaceuticals useful for increasing cardiotonic contractility in humans or other animals. The compounds have the structure (I), wherein A is (II), (III), (IV) or (V); W is N or CR7; X is N or CR8; Y is N or CR9; Z is N or...
|
|
WO/1987/006837A1 |
Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment. The conjugates retain substan...
|
|
WO/1987/004161A1 |
Diastereomers of 10-alkyl-10-deazaminopterins are provided, as well as a synthesis for their preparation as the individual d, L. and l,L.-diastereomers, the d,L-10-ethyl diastereomer being three times as potent against L1210 cells as the...
|
|
WO/1986/001103A1 |
Dehydrated liposomes are prepared by drying liposome preparations under reduced pressure in the presence of one or more protective sugars, e.g., the disaccharides trehalose and sucrose. Preferably, the protective sugars are present at bo...
|
|
WO/1986/001102A1 |
Methods for encapsulating ionizable antineoplastic agents in liposomes using transmembrane potentials. Trapping efficiencies approaching 100% and rapid loading are readily achieved. Dehydration protocols which allow liposomes to be conve...
|
|
WO/1984/004040A1 |
The use of 6, 6-disubstituted pteridines to regulate enzymes, for example, in the treatment of Parkinson's Disease, is disclosed along with a general method of synthesizing these compounds.
|
|
WO/1984/003699A1 |
New 3-amino-tetrahydro-1,3-thiazine-2,4-dione, and skin treatment product based on physiologically compatible carriers and additives, with a certain content of new 3-amino-tetrahydro-1,3-thiazine-2,4-dione derivatives as active agents fo...
|
|
JP7479293B2 |
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).
|
|
JP7473526B2 |
The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid L-leucine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester is from 1:0.3 to 1:3.0 (in mol...
|
|
JP7422124B2 |
The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in m...
|
|
JP7396960B2 |
The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chem...
|
|
JP7395556B2 |
The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and an amino acid ethyl ester like L-phenylalanine ethyl ester or L-methionine ethyl ester, wherein the molar ratio of 5-methyl-(6S)-tetrahy...
|
|
JP2023540491A |
Application of the pteridinone series and/or its pharmaceutically acceptable salts, prodrugs as EGFR non-classical mutation inhibitors. In particular, a series of compounds of formula I, pharmaceutical compositions comprising a series of...
|
